ARTICLE | Clinical News
Cylene Pharmaceuticals preclinical data
April 23, 2012 7:00 AM UTC
In a mouse xenograft model of cancer, CX-8184 showed "potent" antitumor activity and was well tolerated. Additionally, the second-generation oral protein kinase CK2 inhibitor demonstrated broad anti-...